Press Release: Innovative AI-Powered Imaging: Universitäts-Augenklinik Würzburg Integrates RetInSight Software Into AMD Diagnostics
04/2025
Vienna, April 29, 2025 – The Universitäts-Augenklinik Würzburg (University Eye Hospital Würzburg) has become the first university clinic in Germany to incorporate RetInSight’s medical software solutions, Fluid Monitor and GA Monitor, into its routine clinical practice.
Under the leadership of Prof. Jost Hillenkamp, the Universitäts-Augenklinik Würzburg is leveraging AI-powered technology to enhance diagnostic accuracy and inform treatment decisions for age-related macular degeneration (AMD). Since the beginning of the year, RetInSight’s OCT imaging analysis software has been used in the retina and IVOM outpatient clinics for selected patients.
With just a click, the software generates a comprehensive PDF report for patients with AMD. This report supports both diagnosis and disease monitoring, making patient management more efficient. Both software solutions are certified as medical devices under MDR 2017/745. Notably, GA Monitor is currently the only MDR-certified tool available for the diagnosis and monitoring of geographic atrophy.
By adopting this technology, the clinic is gaining valuable practical experience with AI-assisted decision support for exudative neovascular AMD. At the same time, the software enables precise quantification of geographic atrophy, allowing early detection of different progression rates.
Prof. Jost Hillenkamp describes the initial results as promising: “The software provides valuable diagnostic support and could prove highly beneficial in everyday clinical practice for patients with exudative neovascular AMD and geographic atrophy.”
Throughout the rest of the year, the Universitäts-Augenklinik Würzburg plans to further assess the efficiency and clinical value of RetInSight’s software, with the aim of optimizing its use in patient care.
About the RetInSight Fluid Monitor
The RetInSight Fluid Monitor is an AI-based software for the precise and automatic evaluation of OCT images in clinical routine. It allows doctors to instantly recognize and quantify disease-specific fluids in various retinal layers. These fluid accumulations are key indicators of the activity of neovascular age-related macular degeneration (nAMD, wet AMD). The Fluid Monitor provides a clear and visualized PDF report, offering a practical and high-quality basis for assessing disease progression and tailoring treatment for optimal outcomes.
About the RetInSight GA Monitor
The RetInSight GA Monitor is an AI-based software for the interpretation of OCT images as part of the management of geographic atrophy (GA), the dry form of AMD.
This disease leads to severe, irreversible vision loss. The GA Monitor visualizes, localizes and quantifies the degeneration of the photoreceptors (PR) and the loss of the retinal pigment epithelium (RPE) in the retina long before this is recognizable in clinical routine. Within minutes, it creates a clear, one-page PDF report that is available to the ophthalmologist at the click of a mouse.
The software thus enables, for the first time, a comprehensive and early recording of the activity and stage of GA, which was previously not possible for the ophthalmologist using routine methods. In addition, the report’s easy-to-understand images support patient communication in this serious chronic disease.
About Universitäts-Augenklinik Würzburg
Universitäts-Augenklinik Würzburg is a leading tertiary care center covering all areas of ophthalmology. By utilizing and advancing state-of-the-art diagnostic and therapeutic methods, the clinic actively contributes to the ongoing development of ophthalmology.
About RetInSight
RetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy. We are therefore developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world. Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data.
Contact Universitäts-Augenklinik Würzburg
Universitäts-Augenklinik Würzburg
Andreas Berlin
Josef-Schneider-Str. 11, 97080 Würzburg, Germany
Tel: +49 931-20-20601
https://www.ukw.de/augenklinik/
Media Contact RetInSight
RetInSight GmbH
Klaudia Schuh, Head of Marketing & Communications
Tel: +43 677 610 749 47
E-Mail: klaudia.schuh@retinsight.com
www.retinsight.com